Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Calderasib - Merck Sharp & Dohme Corp.

Next Previous
Drug Profile

Calderasib - Merck Sharp & Dohme Corp.

Alternative Names: MK-1084

Latest Information Update: 05 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme Corp.
  • Class Alkanes; Alkenes; Antineoplastics; Chlorinated hydrocarbons; Cyclic ethers; Fluorobenzenes; Heterocyclic compounds with 4 or more rings; Ketones; Piperazines; Pyridines; Pyrimidinones; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Adenocarcinoma; Non-small cell lung cancer
  • Phase II Solid tumours

Most Recent Events

  • 05 May 2026 Merck Sharp & Dohme plans a phase III MK-1084-015/​KANDLELIT-015 trial for Non small cell lung cancer (Late stage disease, Unresected/Inoperable, Combination therapy, Second line therapy or greater) (PO, Tablet) in June 2026 (NCT07554339) (EUCT2025-522038-29-00)
  • 09 Apr 2026 3926911 - Updated KDM and added sci data, reverted NDR, added missing dev line
  • 17 Mar 2026 Updated efficacy and adverse event data from the phase I KANDLELIT-001 trial in Solid tumours presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top